MarginsXMarginsX
Home › Markets › Health Care › IMUX

Immunic Inc. (IMUX)

IMUX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.23
-3.86% on the day
Market cap
$114.8M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerIMUX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001280776
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
16.5 months
$132.0M cash at September 30, 2026
Share count, 1 year
+32.0%
2025-11-07 to 2026-11-06 · +251.8% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$132.0M cash; operating cash flow -$24.0M a quarter.Report 2026-09-30
Shares outstanding15,880,822 (2026-11-06); 120,284,724 a year earlier; 45,145,383 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-10 on 2026-04-27Source 2026-04-27
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-04-02
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-01-06
AuditorBaker Tilly US, LLP, Minneapolis, Minnesota, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$42.3M-$28.4M$132.0MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q2 2026
2026-06-30
Not filed-$34.1M-$31.0M$155.1MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q1 2026
2026-03-31
Not filed-$32.6M-$17.3M$186.6MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q4 2025
2025-12-31
Not filed-$19.3M-$19.3M$15.5MNo debt tagsNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
Not filed-$25.6M-$20.1M$35.1MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q2 2025
2025-06-30
Not filed-$26.8M-$24.6M$55.3MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q1 2025
2025-03-31
Not filed-$25.5M-$21.8M$14.3MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q4 2024
2024-12-31
Not filed-$25.2M-$23.0M$35.7MNo debt tagsNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-04-02
Latest annual report10-K/A2026-04-22
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEF 14A2026-05-29

Source: SEC EDGAR submissions feed, 837 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.0%
1 month+9.1%
3 months-54.6%
Year to date+40.8%
1 year+5.5%
From 52-week high-55.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M
UPBUpstream Bio Inc.$2.15-22.66%$117.8M
CATXPerspective Therapeutics Inc.$0.9238-2.05%$111.6M
OKUROnKure Therapeutics Inc.$2.75+4.56%$111.4M
NERVMinerva Neurosciences Inc$2.20-4.35%$109.6M
SPRBSpruce Biosciences Inc.$42.25-2.45%$121.4M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M
BGMBGM Group Ltd.$8.01+1.71%$107.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier